Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Multiplicom Appoints Board Chairman

Published: Thursday, June 27, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Appointment of Dr Ian Gilham as Chairman of the Board of Directors.

Multiplicom NV has announced that Dr Ian Gilham has been appointed as Chairman of the Board of Directors.

"We are delighted that Ian has decided to join our team, strengthening the Board at this important time in the company’s development” said Dirk Pollet CEO of Multiplicom.

Pollet continued, “Ian has worked with many companies providing them with valuable experience in research, development and the commercialization of products. We look forward to working with him and have every confidence that his expertise will help us grow the company and deliver value for both new and existing investors.”

Dr. Gilham was Chief Executive Officer of Axis-Shield plc, a public in-vitro diagnostics company, until Alere acquired it in November 2011.

Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008.

Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogenetic tests, as well as novel diagnostic tests used in targeting GSK’s medicines.

Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of clinical diagnostics and pharmaceuticals.

Commenting on his appointment, Dr Ian Gilham said: “It is with great pleasure that I have accepted the opportunity to become Chairman to the Board of Multiplicom. The molecular diagnostics market is undergoing rapid growth, fuelled by the decreasing cost of DNA sequencing and increased availability of genetic information that links genes to health and disease. The outlook is very promising for the genomic and somatic mutations that Multiplicom is focused on. I look forward to working with the Board to make sure the company fulfills its clearly evident potential.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Multiplicom Receives €1.9m Grant
Multiplicom has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers.
Thursday, May 26, 2016
Multiplicom’s BRCA MASTR™ Dx Test Accredited with CE/IVD Mark
BRCA MASTR Dx will be shipped throughout Europe from September 2012.
Wednesday, June 20, 2012
Multiplicom Receives €200,000 Grant for Novel Non-Invasive Pre-Natal Test
IWT grant to support development of early aneuploidy detection during pregnancy.
Thursday, June 07, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Potential Urine Test for CJD
Researchers at the Medical Research Council (MRC) Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos